Is the flu wave a positive catalyst for Walgreens stock?

Yes, in the short term. Walgreens reports very high Tamiflu demand and a 61% jump in at-home flu test sales, which can lift scripts and baskets. The key is duration. If activity stays strong into January, comps benefit. If it fades fast, the boost to Walgreens stock may be brief.

What does the “super flu variant” mean for Walgreens stock?

Media report a “super flu variant” tied to H3N2 spread. If severity and cases stay high, Tamiflu demand and flu test sales can remain elevated. That supports near-term revenue for Walgreens stock, though inventory, staffing, and pricing decisions will shape how much demand converts to earnings.

What risks could offset flu-driven upside for Walgreens stock?

Stockouts, shipping delays, and higher procurement costs can squeeze margins. High leverage at 4.04x debt-to-equity and a 0.605 current ratio also limit flexibility. If flu cases peak early or consumer spending slows, the benefit to Walgreens stock could be smaller and shorter than bulls expect.

What technical levels and signals matter right now?

RSI at 100 and ADX at 50 show a strong, overbought setup. Keltner levels cluster near $11.60 to $12.26 with a $11.93 midline, and ATR is 0.16. With Walgreens stock quoted at $11.98, traders should manage pullback risk and watch the 50-day average at $11.6626 as a near support.

Law and Government

WBA Stock Today: December 26 Flu Wave Lifts Tamiflu, Test Demand

ByHuzaifa Zahoor December 26, 2025December 26, 2025

Walgreens stock is in focus today as a strong flu surge boosts pharmacy traffic and scripts. Walgreens reports very high Tamiflu demand and a 61% jump in OTC at-home flu test sales tied to an early H3N2 “subclade K” season. The recent quote shows $11.98 for Walgreens Boots Alliance (WBA), with a $10.37 billion market cap and a 52-week range of $8.08 to $13.25. Investors now watch January peaks and CDC-tracked hotspots to gauge how long flu strength can support revenue and operating leverage for Walgreens stock.